Paratek Pharmaceuticals Overview

  • Founded
  • 1996

Founded
  • Status
  • Public

  • Employees
  • 208

Employees
  • Stock Symbol
  • PRTK

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $2.14

  • (As of Thursday Closing)

Paratek Pharmaceuticals General Information

Description

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 75 Park Plaza
  • 4th Floor
  • Boston, MA 02116
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Paratek Pharmaceuticals Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.14 $1.94 $1.60 - $7.37 $117M 54.5M 651K -$1.18

Paratek Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 315,790 369,009 388,211 171,267
Revenue 128,901 120,951 43,517 16,544
EBITDA (40,192) (40,742) (77,238) (115,660)
Net Income (58,648) (59,084) (96,541) (128,790)
Total Assets 170,157 183,869 176,853 251,079
Total Debt 257,012 255,736 252,018 262,823
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Paratek Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Paratek Pharmaceuticals‘s full profile, request access.

Request a free trial

Paratek Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Paratek Pharmaceuticals‘s full profile, request access.

Request a free trial

Paratek Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on te
Pharmaceuticals
Boston, MA
208 As of 2021
00000
000000 - 000 00000

00000

esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
0000 000000000
Carlsbad, CA
000 As of 0000
0000
0.000 0000-00-00
00000000000 0000

000000

e velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
000000000000000
Watertown, MA
00 As of 0000
00000
000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Paratek Pharmaceuticals Competitors (64)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ionis Pharmaceuticals Corporate Backed or Acquired Carlsbad, CA 000 0000 00000000000 0000
0000000000 0000000 Formerly VC-backed Watertown, MA 00 00000 000000&0 00000
0000000 0000000000 Formerly VC-backed Dallas, TX 00 00000 000000&0 00000
00000000 Formerly VC-backed Jersey City, NJ 00 00000 000000000 00000
00000 000000000000 Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
You’re viewing 5 of 64 competitors. Get the full list »

Paratek Pharmaceuticals Patents

Paratek Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3095102-A1 Process for making sarecycline hydrochloride Pending 06-Apr-2018 0000000000
AU-2019248350-A1 Process for making sarecycline hydrochloride Pending 06-Apr-2018 0000000000
JP-2021520385-A How to make sale cyclin hydrochloride Pending 06-Apr-2018 0000000000
US-20210017123-A1 Process for making sarecycline hydrochloride Pending 06-Apr-2018 0000000000
EP-3774723-A1 Process for making sarecycline hydrochloride Pending 06-Apr-2018 C07C231/12
To view Paratek Pharmaceuticals’s complete patent history, request access »

Paratek Pharmaceuticals Executive Team (23)

Name Title Board Seat Contact Info
Evan Loh MD Chief Executive Officer & Board Member
Adam Woodrow Executive & President
Sarah Higgins Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Randall Brenner Executive
Walter Gilbert Ph.D Co-Founder
You’re viewing 5 of 23 executive team members. Get the full list »

Paratek Pharmaceuticals Board Members (12)

Name Representing Role Since
Evan Loh MD Paratek Pharmaceuticals Chief Executive Officer & Board Member 000 0000
Jeffrey Stein Ph.D Self Board Member 000 0000
Kristine Peterson Paratek Pharmaceuticals Board Member 000 0000
Michael Bigham Paratek Pharmaceuticals Chairman & Board Member 000 0000
Minnie Baylor-Henry JD Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Paratek Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Paratek Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Paratek Pharmaceuticals‘s full profile, request access.

Request a free trial

Paratek Pharmaceuticals Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 000 30-Oct-2014 0000000000 000.00 Pharmaceuticals
To view Paratek Pharmaceuticals’s complete acquisitions history, request access »